Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
AstraZeneca
Dow
Mallinckrodt
Boehringer Ingelheim

Last Updated: January 27, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Sapacitabine

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Sapacitabine?

Sapacitabine is an investigational drug.

There have been 9 clinical trials for Sapacitabine. The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2011.

The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are Cyclacel Pharmaceuticals, Inc., Dana-Farber Cancer Institute, and AstraZeneca.

There are forty-one US patents protecting this investigational drug and three hundred and four international patents.

Recent Clinical Trials for Sapacitabine
TitleSponsorPhase
Olaparib + Sapacitabine in BRCA Mutant Breast CancerAstraZenecaPhase 1/Phase 2
Olaparib + Sapacitabine in BRCA Mutant Breast CancerCyclacel Pharmaceuticals, Inc.Phase 1/Phase 2
Olaparib + Sapacitabine in BRCA Mutant Breast CancerDana-Farber Cancer InstitutePhase 1/Phase 2

See all Sapacitabine clinical trials

Clinical Trial Summary for Sapacitabine

Top disease conditions for Sapacitabine
Top clinical trial sponsors for Sapacitabine

See all Sapacitabine clinical trials

US Patents for Sapacitabine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Sapacitabine   Start Trial Nucleic acid vaccines ModernaTX, Inc. (Cambridge, MA)   Start Trial
Sapacitabine   Start Trial Polynucleotides encoding immune modulating polypeptides ModernaTX, Inc. (Cambridge, MA)   Start Trial
Sapacitabine   Start Trial Manufacturing methods for production of RNA transcripts ModernaTX, Inc. (Cambridge, MA)   Start Trial
Sapacitabine   Start Trial Formylated N-heterocyclic derivatives as FGFR4 inhibitors NOVARTIS AG (Basel, CH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Sapacitabine

Drugname Country Document Number Estimated Expiration Related US Patent
Sapacitabine Australia 2015249553 2034-04-23   Start Trial
Sapacitabine Brazil 112016024644 2034-04-23   Start Trial
Sapacitabine Canada 2946751 2034-04-23   Start Trial
Sapacitabine China 106659803 2034-04-23   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Johnson and Johnson
McKesson
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.